Sono-Tek Corporation (NASDAQ: SOTK) Q2 2026 Earnings Call | 10/14/2025

Overview: Sono-Tek Corporation, a leader in ultrasonic coating systems, reported its Q2 and first half fiscal 2026 results, showcasing modest revenue growth, record first-half revenues, and strong net income growth. The company highlighted its diversification strategy, with significant momentum in the medical device sector offsetting slower clean energy demand. A robust backlog and strong balance sheet support a positive outlook for modest full-year revenue growth.

Key Financial Highlights:

• Q2 2026:
  • Revenue: Slightly up to $5.16 million from $5.15 million in Q2 2025, marking the sixth consecutive quarter above $5 million.
  • Gross Profit: Increased 3% to $2.6 million (50% margin vs. 49% last year), driven by a favorable product mix of high-ASP systems and lower warranty costs.
  • Operating Expenses: Decreased to $2.17 million from $2.23 million, due to lower marketing, selling, and R&D expenses, partially offset by higher G&A costs.
  • Net Income: Rose 27% to $424,000 ($0.03 per share) from $341,000 ($0.02 per share).
• First Half 2026:
  • Revenue: Record $10.3 million, up slightly from $10.19 million in H1 2025.
  • Gross Profit: Up 6% to $5.3 million (51% margin vs. 49%), driven by product mix and favorable warranty expenses.
  • Operating Expenses: Slightly down to $4.35 million from $4.45 million.
  • Net Income: Increased 36% to $917,000 ($0.06 per share) from $672,000 ($0.04 per share).
• Balance Sheet: Cash and marketable securities at $10.6 million, no debt, and CapEx of $113,000 for facility upgrades (full-year CapEx expected at $300,000).

Business and Operational Highlights:

• Core Technology: Sono-Tek’s ultrasonic coating systems provide precision thin-film coatings, reducing material waste and supporting environmental compliance. The shift to complex, high-ASP systems (often >$300,000, some >$1 million) has driven growth.
• Diversification Strategy: Strong growth in the medical device sector (e.g., balloon catheter coating systems) offset a decline in clean energy orders due to U.S. policy shifts. Notable orders include a $5 million and a $2.8 million medical device contract.
• Market Performance:
  • Medical: Q2 sales surged 150% ($602,000) to $1 million; H1 up 44% ($553,000), driven by balloon coating systems in the U.S., Europe, and China.
  • Clean Energy: Q2 sales down 3% ($65,000) to $2.43 million; H1 up 90% ($901,000), led by solar coating systems.
  • Electronics: Q2 down 1% ($22,000); H1 down 21% ($646,000) due to timing of semiconductor orders.
  • Industrial: Q2 down 68% ($517,000); H1 down 67% ($711,000), impacted by non-repeating FY2025 orders.
• Geographic Performance:
  • U.S./Canada: Q2 sales down 22% ($775,000); H1 down 5% ($324,000) due to clean energy slowdown.
  • Asia: Q2 sales up 153% ($562,000); H1 up 74% ($647,000), driven by medical and clean energy sales in China, Japan, and South Korea.
  • EMEA: Q2 up 25% ($288,000); H1 flat ($60,000 decline).
  • Latin America: Q2 down $74,000; H1 down $160,000 due to weaker fluxing sales.
• Backlog: Near-record $11.2 million, reflecting strong order activity, with large medical orders expected to ship primarily in FY2027.
• R&D Investment: $1.3 million in H1 2026 (vs. $1.4 million in H1 2025), supporting product expansion and high-ASP system development.
• Forward-Deployed Engineering (FDE): The FDE model, involving engineers working directly in customer production environments, enhances system adoption, shortens sales cycles, and drives high-ASP system sales (60-70% of shipments tied to lab testing/FDE).

Strategic and Market Insights:

• Medical Device Momentum: Strong demand for balloon catheter and stent coating systems, with Sono-Tek establishing itself as an industry standard. The company’s advanced platforms offer higher ASPs and improved margins compared to earlier stent systems.
• Clean Energy: Despite anticipated declines due to U.S. policy shifts, commercial demand from solar and carbon capture customers remains robust.
• Semiconductor Opportunity: Recent success at a trade show (SemiCon) highlighted expanded product offerings, increasing interest in 300mm fab-directed systems, signaling future growth potential.
• China Market: Despite competition from lower-cost local vendors, Sono-Tek secured medical device orders in China due to superior quality, even at premium prices amidst tariffs.
• Trade/Tariff Resilience: Over 50% of sales are U.S.-based, and key components are manufactured domestically, minimizing tariff exposure.

Outlook:

• Full-Year FY2026: Updated guidance reflects modest revenue growth, balancing caution around clean energy policy shifts with optimism for medical device demand. The company expects continued margin expansion as high-ASP systems scale.
• Long-Term: Sono-Tek is confident in sustained growth, driven by its shift to complex, customized systems, proprietary technology, and diversified market exposure (medical, clean energy, semiconductors). Margin benefits from FDE and high-ASP systems are expected to materialize over the next 1-2 years.